Please use this identifier to cite or link to this item: http://ir.mu.ac.ke:8080/jspui/handle/123456789/3032
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrinkhof, W. G. Martin-
dc.contributor.authorEgger, Matthias-
dc.contributor.authorBoulle, Andrew-
dc.contributor.authorMay, Margaret-
dc.contributor.authorHosseinipour, Mina-
dc.contributor.authorSprinz, Eduardo-
dc.date.accessioned2020-03-16T12:18:32Z-
dc.date.available2020-03-16T12:18:32Z-
dc.date.issued2007-12-
dc.identifier.urihttp://ir.mu.ac.ke:8080/jspui/handle/123456789/3032-
dc.description.abstractWe examined the incidence of and risk factors for tuber- culosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the inci- dence of tuberculosis associated with highly active antiret- roviral therapy was similar: the rate ratio for months 7–12 versus months 1–3 was 0.48 (95% confidence interval, 0.36– 0.64) in low-income countries and 0.36 (95% confidence in- terval, 0.26–0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settingsen_US
dc.language.isoenen_US
dc.publisherAmpathen_US
dc.subjectTuberculosisen_US
dc.subjectAntiretroviralen_US
dc.subjectTherapyen_US
dc.subjectLow-Incomeen_US
dc.subjectHigh-Incomeen_US
dc.titleTuberculosis after initiation of antiretroviral therapy in low-income and high-income countriesen_US
dc.typeArticleen_US
Appears in Collections:School of Medicine

Files in This Item:
File Description SizeFormat 
Brinkhof, M.W.G. etal 2007.pdf126.24 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.